journal article·2023-10Open access

Bone‐Targeted Delivery of Cell‐Penetrating‐RUNX2 Fusion Protein in Osteoporosis Model

Seoyeon Kim, Haein Lee, Jiyeon Hong, Seung Hyun L. Kim, Euntaek Kwon, Tai Hyun Park, Nathaniel S. Hwang

Advanced Science· Volume 10· Issue 28

Abstract

Abstract The onset of osteoporosis leads to a gradual decrease in bone density due to an imbalance between bone formation and resorption. To achieve optimal drug efficacy with minimal side effects, targeted drug delivery to the bone is necessary. Previous studies have utilized peptides that bind to hydroxyapatite, a mineral component of bone, for bone‐targeted drug delivery. In this study, a hydroxyapatite binding (HAB) tag is fused to 30Kc19α‐Runt‐related transcription factor 2 (RUNX2) for bone‐targeting. This recombinant protein can penetrate the nucleus of human mesenchymal stem cells (hMSCs) and act as a master transcription factor for osteogenesis. The HAB tag increases the binding affinity of 30Kc19α‐RUNX2 to mineral deposition in mature osteoblasts and bone tissue, without affecting its osteogenic induction capability. In the osteoporosis mouse model, intravenous injection of HAB‐30Kc19α‐RUNX2 results in preferential accumulation in the femur and promotes bone formation while reducing toxicity in the spleen. These findings suggest that HAB‐30Kc19α‐RUNX2 may be a promising candidate for bone‐targeted therapy in osteoporosis.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Bone Metabolism and Diseases · Bone health and treatments · Orthopaedic implants and arthroplasty

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Chemical and Biological Engineering Institute of Chemical Processes Seoul National University 1 Gwanak‐ro, Gwanak‐gu Seoul 08826 Republic of Korea

Interdisciplinary Program in Bioengineering Seoul National University 1 Gwanak‐ro, Gwanak‐gu Seoul 08826 Republic of Korea

BioMAX/N‐Bio Institute Institute of BioEngineerig Seoul National University 1 Gwanakro, Gwanak‐gu Seoul 08826 Republic of Korea

Department of Nutritional Science and Food Management Ewha Womans University 52, Ewhayeodae‐gil, Seodaemun‐gu Seoul 03760 Republic of Korea

Funding

Ministry of Science and ICT, South Korea

References (63)

Show source-provided references
1. Clynes M. A. · Br. Med. Bull. · 2020 · 133 · 105
2. b)E. M.Curtis N. C.Harvey C.Cooper in CRC Press2018 1 1.10.1201/9781351234627-1 ↗
3. 10.1007/s13224-019-01213-710.1007/s13224-019-01213-7 ↗
4. Li L. · Ovarian Aging and Osteoporosis · 2018 · 1086 · 199
5. 10.5152/eurjrheum.2016.04810.5152/eurjrheum.2016.048 ↗
6. Clynes M. A. · British Med. Bull. · 2020 · 133 · 105
7. 10.1111/bph.1502410.1111/bph.15024 ↗
8. 10.1111/jcpt.1261610.1111/jcpt.12616 ↗
9. 10.1016/j.heliyon.2022.e1228810.1016/j.heliyon.2022.e12288 ↗
10. 10.11622/smedj.201902810.11622/smedj.2019028 ↗
11. 10.1016/S2213-8587(17)30188-210.1016/S2213-8587(17)30188-2 ↗
12. 10.1021/acsbiomaterials.0c0082710.1021/acsbiomaterials.0c00827 ↗
13. 10.1016/j.bone.2010.02.02710.1016/j.bone.2010.02.027 ↗
14. 10.1038/s41598-018-31853-010.1038/s41598-018-31853-0 ↗
15. Xu J. · Am. J. Transl. Res. · 2015 · 7 · 2527
16. 10.1016/j.biomaterials.2012.08.06310.1016/j.biomaterials.2012.08.063 ↗
17. 10.1002/biot.20160004010.1002/biot.201600040 ↗
18. 10.1016/j.biomaterials.2013.11.00110.1016/j.biomaterials.2013.11.001 ↗
19. 10.1002/biot.20140025310.1002/biot.201400253 ↗
20. 10.1016/j.procbio.2011.10.02210.1016/j.procbio.2011.10.022 ↗
21. 10.3390/ijms1807134510.3390/ijms18071345 ↗
22. 10.1186/s40824-018-0153-710.1186/s40824-018-0153-7 ↗
23. 10.2174/138945012166620073117352210.2174/1389450121666200731173522 ↗
24. 10.3390/ijms2209485410.3390/ijms22094854 ↗
25. 10.1111/j.1365-4632.2004.02108.x10.1111/j.1365-4632.2004.02108.x ↗
26. 10.1016/j.jconrel.2019.04.04210.1016/j.jconrel.2019.04.042 ↗
27. 10.2147/IJN.S13378710.2147/IJN.S133787 ↗
28. 10.1016/j.biomaterials.2017.10.05310.1016/j.biomaterials.2017.10.053 ↗
29. 10.1021/acsbiomaterials.1c0015010.1021/acsbiomaterials.1c00150 ↗
30. 10.3390/ijms2209493910.3390/ijms22094939 ↗
31. 10.1021/acsbiomaterials.0c0134910.1021/acsbiomaterials.0c01349 ↗
32. 10.1016/j.cdtm.2015.02.00610.1016/j.cdtm.2015.02.006 ↗
33. 10.1016/j.bbamcr.2019.06.01410.1016/j.bbamcr.2019.06.014 ↗
34. 10.3390/ijms2204156810.3390/ijms22041568 ↗
35. 10.1111/clr.1236010.1111/clr.12360 ↗
36. 10.22203/eCM.v028a1910.22203/eCM.v028a19 ↗
37. 10.1074/jbc.M50075020010.1074/jbc.M500750200 ↗
38. 10.1002/jcb.2095810.1002/jcb.20958 ↗
39. 10.1016/j.bone.2011.07.02710.1016/j.bone.2011.07.027 ↗
40. 10.1016/S0092-8674(00)80257-310.1016/S0092-8674(00)80257-3 ↗
41. 10.1016/S0092-8674(00)80258-510.1016/S0092-8674(00)80258-5 ↗
42. 10.1038/nn.265810.1038/nn.2658 ↗
43. 10.1161/CIRCRESAHA.116.30983310.1161/CIRCRESAHA.116.309833 ↗
44. 10.1016/j.gendis.2017.10.00410.1016/j.gendis.2017.10.004 ↗
45. Huang Y. · Pain Res. Treat. · 2011 · 2011
46. 10.4103/2277-9175.9815210.4103/2277-9175.98152 ↗
47. Ramamoorth M. · J. Clin. Diagnos. Res.: JCDR · 2015 · 9 · GE01
48. 10.1021/acs.biomac.1c0069710.1021/acs.biomac.1c00697 ↗
49. 10.3762/bjnano.11.1010.3762/bjnano.11.10 ↗
50. 10.1016/j.procbio.2014.05.00810.1016/j.procbio.2014.05.008 ↗
51. 10.1002/adbi.20200017610.1002/adbi.202000176 ↗
52. 10.1016/j.biocel.2020.10571710.1016/j.biocel.2020.105717 ↗
53. 10.1007/s11095-008-9706-010.1007/s11095-008-9706-0 ↗
54. 10.1021/acsbiomaterials.1c0015010.1021/acsbiomaterials.1c00150 ↗
55. 10.4103/0976-500X.11972610.4103/0976-500X.119726 ↗
56. 10.1021/acsbiomaterials.0c0134910.1021/acsbiomaterials.0c01349 ↗
57. 10.1016/j.ijpharm.2014.08.06710.1016/j.ijpharm.2014.08.067 ↗
58. 10.1016/j.ab.2004.02.00210.1016/j.ab.2004.02.002 ↗
59. 10.1359/jbmr.1999.14.3.39610.1359/jbmr.1999.14.3.396 ↗
60. 10.1074/jbc.M50394220010.1074/jbc.M503942200 ↗
61. Lasota A. · Rocz Akad Med Bialymst · 2004 · 49 · 129
62. 10.1038/bonekey.2014.10910.1038/bonekey.2014.109 ↗
63. 10.1002/adhm.20210007010.1002/adhm.202100070 ↗